The World Health is set to commence testing of Ebola vaccines in Switzerland this week, after been given the approval by the authorities, tuesday.
Swiss authorities announced they would allow trials of an experimental vaccine produced by British pharmaceutical
GlaxoSmithKine, and would conduct tests on some 120 individuals at the CHUV hospital in Lausanne Friday, the hospital said.
“We have never before received so many volunteers so quickly,” Blaise Genton, who heads CHUV’s infectuous
disease division told reporters.
He said the volunteers, who must be between the ages of 18 and 65, were mainly medical students and would
all receive 800 Swiss francs ($845, 665 euros) for their participation.
Genton stressed they would receive payment for their time, since they would be spending “numerous hours with us”.
Most of the volunteers will receive the experimental GSK vaccine called ChAd3, which is based on a genetically modified chimpanzee adenovirus, but 20 of
them would receive a placebo (dummy medicine containing no active ingredients)
source: TheTrent
No comments:
Post a Comment